201 related articles for article (PubMed ID: 33401995)
21. Report of a Chinese Cohort with Activated Phosphoinositide 3-Kinase δ Syndrome.
Wang Y; Wang W; Liu L; Hou J; Ying W; Hui X; Zhou Q; Liu D; Yao H; Sun J; Wang X
J Clin Immunol; 2018 Nov; 38(8):854-863. PubMed ID: 30499059
[TBL] [Abstract][Full Text] [Related]
22. APDS2 and SHORT Syndrome in a Teenager with PIK3R1 Pathogenic Variant.
Ramirez L; Tamayo W; Ale H
J Clin Immunol; 2020 Oct; 40(7):1020-1025. PubMed ID: 32778990
[TBL] [Abstract][Full Text] [Related]
23. Identification of a novel de novo gain-of-function mutation of PIK3CD in a patient with activated phosphoinositide 3-kinase δ syndrome.
Luo Y; Xia Y; Wang W; Li Z; Jin Y; Gong Y; He T; Li Q; Li C; Yang J
Clin Immunol; 2018 Dec; 197():60-67. PubMed ID: 30138677
[TBL] [Abstract][Full Text] [Related]
24. Disorders Related to PI3Kδ Hyperactivation: Characterizing the Clinical and Immunological Features of Activated PI3-Kinase Delta Syndromes.
Redenbaugh V; Coulter T
Front Pediatr; 2021; 9():702872. PubMed ID: 34422726
[TBL] [Abstract][Full Text] [Related]
25. Case Report: Activating
Lu M; Gu W; Sheng Y; Wang J; Xu X
Front Immunol; 2021; 12():670312. PubMed ID: 33995405
[TBL] [Abstract][Full Text] [Related]
26. Activated Phosphoinositide 3-Kinase δ Syndrome: a Large Pediatric Cohort from a Single Center in China.
Qiu L; Wang Y; Tang W; Yang Q; Zeng T; Chen J; Chen X; Zhang L; Zhou L; Zhang Z; An Y; Tang X; Zhao X
J Clin Immunol; 2022 May; 42(4):837-850. PubMed ID: 35296988
[TBL] [Abstract][Full Text] [Related]
27. Human PIK3R1 mutations disrupt lymphocyte differentiation to cause activated PI3Kδ syndrome 2.
Nguyen T; Lau A; Bier J; Cooke KC; Lenthall H; Ruiz-Diaz S; Avery DT; Brigden H; Zahra D; Sewell WA; Droney L; Okada S; Asano T; Abolhassani H; Chavoshzadeh Z; Abraham RS; Rajapakse N; Klee EW; Church JA; Williams A; Wong M; Burkhart C; Uzel G; Croucher DR; James DE; Ma CS; Brink R; Tangye SG; Deenick EK
J Exp Med; 2023 Jun; 220(6):. PubMed ID: 36943234
[TBL] [Abstract][Full Text] [Related]
28. Clinical practice guideline for activated phosphatidyl inositol 3-kinase-delta syndrome in Japan.
Moriya K; Mitsui-Sekinaka K; Sekinaka Y; Endo A; Kanegane H; Morio T; Imai K; Nonoyama S
Immunol Med; 2023 Dec; 46(4):153-157. PubMed ID: 37178059
[TBL] [Abstract][Full Text] [Related]
29. Case Report: First Occurrence of Plasmablastic Lymphoma in Activated Phosphoinositide 3-Kinase δ Syndrome.
Yin Z; Tian X; Zou R; He X; Chen K; Zhu C
Front Immunol; 2021; 12():813261. PubMed ID: 34992612
[TBL] [Abstract][Full Text] [Related]
30. Disseminated and Congenital Toxoplasmosis in a Mother and Child With Activated PI3-Kinase δ Syndrome Type 2 (APDS2): Case Report and a Literature Review of Toxoplasma Infections in Primary Immunodeficiencies.
Karanovic D; Michelow IC; Hayward AR; DeRavin SS; Delmonte OM; Grigg ME; Dobbs AK; Niemela JE; Stoddard J; Alhinai Z; Rybak N; Hernandez N; Pittaluga S; Rosenzweig SD; Uzel G; Notarangelo LD
Front Immunol; 2019; 10():77. PubMed ID: 30891027
[TBL] [Abstract][Full Text] [Related]
31. Activating PI3Kδ mutations in a cohort of 669 patients with primary immunodeficiency.
Elgizouli M; Lowe DM; Speckmann C; Schubert D; Hülsdünker J; Eskandarian Z; Dudek A; Schmitt-Graeff A; Wanders J; Jørgensen SF; Fevang B; Salzer U; Nieters A; Burns S; Grimbacher B
Clin Exp Immunol; 2016 Feb; 183(2):221-9. PubMed ID: 26437962
[TBL] [Abstract][Full Text] [Related]
32. Phosphatase and tensin homolog (PTEN) mutation can cause activated phosphatidylinositol 3-kinase δ syndrome-like immunodeficiency.
Tsujita Y; Mitsui-Sekinaka K; Imai K; Yeh TW; Mitsuiki N; Asano T; Ohnishi H; Kato Z; Sekinaka Y; Zaha K; Kato T; Okano T; Takashima T; Kobayashi K; Kimura M; Kunitsu T; Maruo Y; Kanegane H; Takagi M; Yoshida K; Okuno Y; Muramatsu H; Shiraishi Y; Chiba K; Tanaka H; Miyano S; Kojima S; Ogawa S; Ohara O; Okada S; Kobayashi M; Morio T; Nonoyama S
J Allergy Clin Immunol; 2016 Dec; 138(6):1672-1680.e10. PubMed ID: 27426521
[TBL] [Abstract][Full Text] [Related]
33. Genetic Defects in Phosphoinositide 3-Kinase δ Influence CD8
Cannons JL; Preite S; Kapnick SM; Uzel G; Schwartzberg PL
Front Immunol; 2018; 9():1758. PubMed ID: 30116245
[TBL] [Abstract][Full Text] [Related]
34. Phosphoinositide 3-kinase δ gene mutation predisposes to respiratory infection and airway damage.
Angulo I; Vadas O; Garçon F; Banham-Hall E; Plagnol V; Leahy TR; Baxendale H; Coulter T; Curtis J; Wu C; Blake-Palmer K; Perisic O; Smyth D; Maes M; Fiddler C; Juss J; Cilliers D; Markelj G; Chandra A; Farmer G; Kielkowska A; Clark J; Kracker S; Debré M; Picard C; Pellier I; Jabado N; Morris JA; Barcenas-Morales G; Fischer A; Stephens L; Hawkins P; Barrett JC; Abinun M; Clatworthy M; Durandy A; Doffinger R; Chilvers ER; Cant AJ; Kumararatne D; Okkenhaug K; Williams RL; Condliffe A; Nejentsev S
Science; 2013 Nov; 342(6160):866-71. PubMed ID: 24136356
[TBL] [Abstract][Full Text] [Related]
35. [Clinical and immunological analysis of patients with activated phosphoinositide 3-kinase δ syndrome resulting from PIK3CD mutation].
Tang WJ; Wang W; Luo Y; Wang YP; Li L; An YF; Gou LJ; Ma MS; He TY; Yang J; Zhao XD; Song HM
Zhonghua Er Ke Za Zhi; 2017 Jan; 55(1):19-24. PubMed ID: 28072954
[No Abstract] [Full Text] [Related]
36. Secondary C1q Deficiency in Activated PI3Kδ Syndrome Type 2.
Hong Y; Nanthapisal S; Omoyinmi E; Olbrich P; Neth O; Speckmann C; Lucena JM; Gilmour K; Worth A; ; Klein N; Eleftheriou D; Brogan P
Front Immunol; 2019; 10():2589. PubMed ID: 31781101
[TBL] [Abstract][Full Text] [Related]
37. A Rare Case of Activated Phosphoinositide 3-Kinase Delta Syndrome (APDS) Presenting With Hemophagocytosis Complicated With Hodgkin Lymphoma.
Cansever M; Zietara N; Chiang SCC; Ozcan A; Yilmaz E; Karakukcu M; Rohlfs M; Somekh I; Canoz O; Abdulrezzak U; Bryceson Y; Klein C; Unal E; Patiroglu T
J Pediatr Hematol Oncol; 2020 Mar; 42(2):156-159. PubMed ID: 31033788
[TBL] [Abstract][Full Text] [Related]
38. Modulating the PI3K Signalling Pathway in Activated PI3K Delta Syndrome: a Clinical Perspective.
Berglund LJ
J Clin Immunol; 2023 Dec; 44(1):34. PubMed ID: 38148368
[TBL] [Abstract][Full Text] [Related]
39. The Treatment of Activated PI3Kδ Syndrome.
Coulter TI; Cant AJ
Front Immunol; 2018; 9():2043. PubMed ID: 30245694
[TBL] [Abstract][Full Text] [Related]
40. Hematopoietic stem cell transplantation for progressive combined immunodeficiency and lymphoproliferation in patients with activated phosphatidylinositol-3-OH kinase δ syndrome type 1.
Okano T; Imai K; Tsujita Y; Mitsuiki N; Yoshida K; Kamae C; Honma K; Mitsui-Sekinaka K; Sekinaka Y; Kato T; Hanabusa K; Endo E; Takashima T; Hiroki H; Yeh TW; Tanaka K; Nagahori M; Tsuge I; Bando Y; Iwasaki F; Shikama Y; Inoue M; Kimoto T; Moriguchi N; Yuza Y; Kaneko T; Suzuki K; Matsubara T; Maruo Y; Kunitsu T; Waragai T; Sano H; Hashimoto Y; Tasaki K; Suzuki O; Shirakawa T; Kato M; Uchiyama T; Ishimura M; Tauchi T; Yagasaki H; Jou ST; Yu HH; Kanegane H; Kracker S; Durandy A; Kojima D; Muramatsu H; Wada T; Inoue Y; Takada H; Kojima S; Ogawa S; Ohara O; Nonoyama S; Morio T
J Allergy Clin Immunol; 2019 Jan; 143(1):266-275. PubMed ID: 29778502
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]